These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3076139)

  • 41. Comparison of prazosin and methyldopa in mild to moderate hypertension, a multicenter cooperative study.
    Bradley WF; Hoffman FG; Hutchison JC; Kalams Z; Waldron SL
    Curr Ther Res Clin Exp; 1977 Jan; 21(1):28-35. PubMed ID: 401709
    [No Abstract]   [Full Text] [Related]  

  • 42. Effects of long term treatment with pinacidil and nifedipine on left ventricular anatomy and function in patients with mild to moderate systemic hypertension.
    Steensgaard-Hansen F; Carlsen JE
    Drugs; 1988; 36 Suppl 7():70-6. PubMed ID: 3254831
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Peripheral vasodilatation in the treatment of hypertension. Prazosin compared with hydralazine in patients not responding to beta-receptor blockade.
    Malmberg L; Fagerberg SE; Frithz G
    Acta Med Scand Suppl; 1982; 665():121-4. PubMed ID: 6760680
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Felodipine vs hydralazine: a controlled trial as third line therapy in hypertension. Cooperative Study Group.
    Br J Clin Pharmacol; 1986 Jun; 21(6):621-6. PubMed ID: 2874821
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator.
    Breen EG; Mulhall D; Keogh JA
    Eur J Clin Pharmacol; 1985; 28(4):381-6. PubMed ID: 4029244
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Normal insulin release during sustained hyperglycaemia in hypokalaemic periodic paralysis: role of the potassium channel opener pinacidil in impaired muscle strength.
    Ligtenberg JJ; Van Haeften TW; Van Der Kolk LE; Smit AJ; Sluiter WJ; Reitsma WD; Links TP
    Clin Sci (Lond); 1996 Nov; 91(5):583-9. PubMed ID: 8942397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of nadolol alone and combined with bendroflumethiazide and hydralazine for systemic hypertension.
    Am J Cardiol; 1983 Dec; 52(10):1230-7. PubMed ID: 6359851
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of the efficacy and safety of enalapril plus hydrochlorothiazide plus methyldopa vs standard triple therapy in the treatment of moderate to severe hypertension: results from a multicentre study.
    Leonetti G; Cuspidi C; Sampieri L; Ambrosioni E; Malini PL; Pessina A; Semplicini A; Cinotti G; Morabito S; Rappelli A
    J Hum Hypertens; 1990 Feb; 4(1):5-11. PubMed ID: 2189027
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Double-blind comparison of urapidil and prazosin in the treatment of patients with essential hypertension.
    Kaneko Y
    Drugs; 1988; 35 Suppl 6():156-63. PubMed ID: 3042355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The use of felodipine in the treatment of severe hypertension.
    Muir AL; Wathen CG
    Drugs; 1987; 34 Suppl 3():120-4. PubMed ID: 3327673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of efficacy and safety of pindolol and alpha-methyldopa in treatment of mild to moderate hypertension: results of a double-blind evaluative study.
    Beanlands DS; Allard PP; Wilson M; Orbeck KW; Helman AB; Lefebvre R
    Clin Invest Med; 1978; 1(3-4):139-45. PubMed ID: 391453
    [No Abstract]   [Full Text] [Related]  

  • 52. [A new antihypertensive agent used in a clinical setting].
    Wetzels E; Raschig A; Kaiser HJ
    Med Klin; 1980 Sep; 75(19):688-92. PubMed ID: 7001207
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Guanabenz versus methyldopa in the therapy of mild-to-moderate hypertension.
    Rosendorff C
    S Afr Med J; 1982 Sep; 62(13):435-7. PubMed ID: 7051365
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative antihypertensive effects of guanabenz and methyldopa.
    Walker BR; Deitch MW; Schneider BE; Hare LE
    Clin Ther; 1981; 4(4):275-84. PubMed ID: 7332915
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravenous pinacidil in the acute treatment of hypertension.
    Rijk MC; Thien T
    J Clin Pharmacol; 1987 Jul; 27(7):468-74. PubMed ID: 3308975
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Felodipine in hypertensive patients. A dose finding study in patients refractory to beta-blocker monotherapy.
    Sluiter HE
    Drugs; 1987; 34 Suppl 3():97-106. PubMed ID: 2894980
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The relationship between terazosin dose and blood pressure response in hypertensive patients.
    Achari R; Hosmane B; Bonacci E; O'Dea R
    J Clin Pharmacol; 2000 Oct; 40(10):1166-72. PubMed ID: 11028256
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension.
    D'Arcy V; Laher M; McCoy D; Sullivan P; Walsh CH; Hickey MP
    Eur J Clin Pharmacol; 1985; 28(3):347-9. PubMed ID: 4007040
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of trimazosin and methyldopa in hypertension.
    Aronow WS; Tobis J; Hughes D; Siegel J; Easthope J
    Clin Pharmacol Ther; 1977 Oct; 22(4):425-9. PubMed ID: 332438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lipid and apolipoprotein levels during therapy with pinacidil combined with hydrochlorothiazide.
    Corder CN; Goldberg MR; Alaupovic PA; Price MD; Furste SS
    Eur J Clin Pharmacol; 1992; 42(1):65-70. PubMed ID: 1541318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.